Cocrystal Pharma, Inc. operates as a biotechnology company. The Company focuses on developing novel antiviral therapeutics for hepatitis, influenza viruses, and noroviruses. Cocrystal Pharma serves patients in the United States.

Current Report (Form 8-K | Period ending 2024-11-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cocrystal Pharma (COCP US)

Current Report (Form 8-K | Period ending 2024-11-13)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-10-31)

Current Report (Form 8-K | Period ending 2024-10-09)

Current Report (Form 8-K | Period ending 2024-08-19)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)